ESPE Abstracts

Background: Optimisation of hydrocortisone replacement therapy remains challenging due to complex pharmacokinetics as circulating cortisol is protein bound mainly to corticosteroid-binding globulin (CBG) that has a circadian rhythm.Objective: A detailed analysis of the CBG circadian rhythm and its impact on cortisol exposure during hydrocortisone replacement therapy.Methods: CBG was measured over 24 h in 14 healthy...

Context: Prenatal dexamethasone (Dex) therapy is used in female foetuses with congenital adrenal hyperplasia (CAH) to suppress adrenal androgen excess and prevent virilisation of the external genitalia. The prenatal dexamethasone dose of 20 µg/kg/d has been used for decades in prenatal CAH. Despite the risks for the treated mother and potentially for the unborn child, no clinical study or evaluation had been conducted in order to determine a Dex dose with a scientific rat...

Introduction: Prenatal dexamethasone (Dex) therapy in female fetuses with congenital adrenal hyperplasia (CAH) has been conducted for 40 years but the dose given to the pregnant woman has never been fully evaluated in a randomized clinical trial. Prenatal Dex therapy is associated with potential side effects for both mother and child.Methods: In a study funded by the German Federal Ministry of Education and Research (BMB...